France France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of expertise and increasing political support. However, financing and manufacturing French gene therapies is proving an issue, meaning that France is…

France With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a club of companies altogether contributing some EUR 4.5 billion (USD 5 billion) worth of turnover to the home market and…

France The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation.   A reform-minded and business-oriented administration under President Emmanuel Macron…

France Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier has, for many years, been characterized by its discreet, understated approach and a rugged pragmatism and…

France Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million since 2014. It is, however, the company’s unique positioning right at the confluence between the worlds of medicines and cosmetics…

France France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition. With Brexit uncertainties across the channel and populist tendencies souring the prospects of some of its neighbours, France – under…

France The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is subject to mounting regulatory pressures meaning politics must play a key role. As we advance more and more in healthcare…

France On February 4 in Paris, Minister of Health and Solidarity Agnès Buzyn, Minister of Higher Education, Research and Innovation Frédérique Vidal, Secretary of State to the Minister of Economy and Finance Agnès Pannier-Runacher, and President of the Healthcare Industry Strategic Committee (CSF) and Chairman of the French Federation of Health…

France On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to the Minister of the Economy and Finance, Agnès Pannier-Runacher, as part of the promotional event ‘Choose France,’ designed to promote…

France   LEEM – Les Entreprises du Médicament (Drug Companies)   Key people: Philippe Tcheng, President Philippe Lamoureux, Director LEEM is the French industry association which represents drug companies operating in France and is the most powerful professional organization of drug companies operating in the country. They represent more than 260 member companies,…

France ANSM – Agence Nationale de Sécurité des Médicaments et des Produits de Santé (National Agency for the Safety of Drugs and Health Products)   Key People: Dominique Martin, CEO The National Agency for the Safety of Medicines and Health Products (ANSM) was created by the government in 2011 for strengthening the safety of…

France INCa – Institut National du Cancer (The National Cancer Institute)       The National Cancer Institute (INCa) is the state agency of health and scientific expertise in oncology in charge of coordinating actions to fight against cancer. Created by the public health law of August 9, 2004, it is placed…